Alps Advisors Inc Blueprint Medicines Corp Transaction History

Alps Advisors Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$37.97 - $50.0 $39,260 - $51,700	-1,034 Reduced 2.55%	39,523 $1.78 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $1.67 Million - $2.7 Million	40,557 New	40,557 $1.78 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $198,925 - $404,764	-3,677 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$94.25 - $115.99 $4,147 - $5,103	44 Added 1.21%	3,677 $394,000
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $28,828 - $38,971	356 Added 10.86%	3,633 $374,000
Q1 2021 May 07, 2021	BUY	$90.71 - $108.28 $297,256 - $354,833	3,277 New	3,277 $319,000
Q4 2020 Feb 03, 2021	SELL	$92.08 - $124.48 $6.49 Million - $8.77 Million	-70,486 Closed	0 $0
Q3 2020 Nov 04, 2020	SELL	$66.45 - $92.7 $228,255 - $318,424	-3,435 Reduced 4.65%	70,486 $6.53 Million
Q2 2020 Aug 05, 2020	BUY	$57.09 - $79.27 $4.22 Million - $5.86 Million	73,921 New	73,921 $5.77 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.